Skip to main content
. 2019 Feb 21;4(4):e125693. doi: 10.1172/jci.insight.125693

Figure 1. PP2A activation inhibits lung tumor development in an EGFR-driven TKI-sensitive non–small cell lung carcinoma transgenic model.

Figure 1

(A) Expression of TRE-EGFRL858R was induced with doxycycline, and mice were administered either vehicle control or 100 mg/kg of SMAP every 48 hours. (B) Axial images obtained using MRI before and after treatment with vehicle control or SMAP. (C) H&E-stained sections of lung samples. (D) Quantification of H&E results. (E) Quantification of MRI results. (F) Immunohistochemical staining to detect apoptosis (TUNEL) and proliferation. Scale bar: 100 µm. (G) Quantification of TUNEL. (H) Quantification of PCNA. (I) Immunohistochemical staining of pERK and pAKT. Scale bar: 20 µm. Respective quantifications are represented as mean ± SD. *P < 0.05; ***P < 0.001.